RFA-DP-23-002: Improving Health Outcomes for Patients with Inflammatory Bowel Disease
Closed
This grant is closed. A newer notice from the same program is forecast: Chronic Disease Education and Awareness (CDC-RFA-DP-27-0068). Status: Expected deadline April 30, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2022.
Centers for Disease Control and Prevention - ERA offered grants of up to $800,000 (at least $700,000) to any type of organization. It expected to make one award worth $3.8 million in total. Applications closed on January 9, 2023.
From the official notice on Grants.gov, last changed October 20, 2022. Checked November 7, 2026.
- Award ceiling$800,000
- Award floor$700,000
- Total funding$3.8 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | October 13, 2022 |
|---|---|
| Deadline | January 9, 2023 |
| Archived by Grants.gov | February 15, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Special Eligibility - None.
Is this a realistic fit?
- Past Assistance Programs for Chronic Disease Prevention and Control awards averaged $1.0 million; this notice allows up to $800,000 per award.
- Most of the program's money (45% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
To fill gaps in current inflammatory bowel disease (IBD) research and disease management to support public health practice, the purposes of the announcement are to 1) conduct epidemiological studies through the establishment of a multidisciplinary collaborative network to examine the natural history of IBD, social and psychological factors contributing to IBD, health disparities, and effectiveness of management strategies; 2) design and pilot activities to enhance IBD management (e.g., patients’ self-management, integrated clinical care) to improve overall health and quality of life of patients with IBD; 3) design and pilot education and outreach activities for healthcare providers to improve time to diagnosis and start of effective disease management; and 4) identify health disparities (e.g., race and ethnicity) in IBD management and outcomes and tailor evidence-based interventions to reduce these disparities. The results are expected to improve the understanding of the natural history and epidemiology of IBD, including social and psychosocial factors, and support public health practice, including enhancing clinical and self-management strategies, promoting healthcare provider’s awareness and education, and tailoring interventions to address health disparities, and to improve overall health outcomes among patients with IBD.
Who has won Assistance Programs for Chronic Disease Prevention and Control grants before
From fiscal 2021 to 2025, Assistance Programs for Chronic Disease Prevention and Control (93.945) awarded $453 million across 437 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| National Association of Chronic Disease Directors, Inc. | Georgia | 4 | $23.3 million |
| Michigan Department of Health and Human Services | Michigan | 7 | $9.5 million |
| Emory University | Georgia | 4 | $9.4 million |
| Mississippi State Department of Health | Mississippi | 4 | $9.2 million |
| Health Research, Inc. | New York | 7 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-DP-27-0068, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DP-23-002 still open?
No. It closed on January 9, 2023. A newer notice is forecast: CDC-RFA-DP-27-0068, expected deadline April 30, 2027.
Who can apply for Improving Health Outcomes for Patients with Inflammatory Bowel Disease?
Centers for Disease Control and Prevention - ERA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Improving Health Outcomes for Patients with Inflammatory Bowel Disease?
Closed January 9, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $800,000 each. About $3.8 million in total for one award.
Who has won Assistance Programs for Chronic Disease Prevention and Control grants before?
The largest recipients over five fiscal years were National Association of Chronic Disease Directors, Inc., Michigan Department of Health and Human Services, Emory University. The program made 437 awards worth $453 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)